Zhi Tong Cai Jing·2025-08-15 01:45Core Insights - JD Health's stock rose over 10% following the release of its interim results, with a current price of HKD 60.7 and a trading volume of HKD 2.19 billion [1] Financial Performance - For the six months ending June 30, 2025, JD Health reported revenue of RMB 35.29 billion, a year-on-year increase of 24.5% [1] - Non-IFRS profit for the same period was RMB 3.57 billion, up 35% year-on-year [1] - Net profit attributable to shareholders was RMB 2.596 billion, reflecting a 27.45% increase year-on-year [1] - Basic earnings per share were RMB 0.82 [1] Revenue Breakdown - Revenue for the three months ending June 30, 2025, increased by 23.7% to RMB 18.6 billion compared to the previous year [1] - Revenue from the sale of pharmaceutical and health products rose from RMB 23.9 billion to RMB 29.3 billion, marking a 22.7% increase [1] - Growth in product revenue was driven by an increase in active user numbers, additional purchases by users, higher online penetration rates for pharmaceutical and health products, and a wider range of product categories [1] Service Revenue Growth - Service revenue from online platforms and digital marketing increased by 34.4%, from RMB 4.4 billion to RMB 6 billion [2] - The growth in service revenue was primarily due to an increase in digital marketing service fees, attributed to a rise in the number of advertisers on the platform and consistent growth in transactions [2]